Clinical Tumor Anemia Registry (TAR)

Clinical Registry Describing Treatment Reality of Patients With Cancer-(Therapy)-Induced Anemia

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01795690

Acronym

TAR

Enrollment

1018

Registered

2013-02-21

Start date

2011-12-31

Completion date

2016-02-29

Last updated

2016-02-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anemia

Keywords

Anemia, Cancer, Hemoglobin, Quality of Life, FACT-An, FACT-GP, Erythropoiesis-Stimulating Agents (ESA), Epoetin, Ferric Carboxymaltose, Blood Transfusions

Brief summary

The purpose of this registry is to record information of routine treatment of anemia in cancer patients in Germany. An overview of the current treatment of anemia in German outpatient centers and hospitals will be provided. Primary outcome parameters, e.g. improvement in hemoglobin levels and changes in QoL, as well as patient characteristics of different treatments will be analyzed.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Histologically confirmed malignant disease * Hemoglobin level \< 11 g/dl (female) or \< 12 g/dl (male) * Start of antianemic therapy no more than 7 days prior to informed consent * Performance status 0 - 3 (Karnofsky-Index \>= 40%) * Minimum age: 18 years * Informed written consent

Exclusion criteria

* Hypersensitivity against antianemic therapies * Myelodysplastic Syndrome * Experimental antianemic therapy

Design outcomes

Primary

Measure	Time frame	Description
Documentation of therapies	12 weeks per patient	Overview on the current routine treatment of anemia in cancer patients in Germany

Secondary

Measure	Time frame	Description
Change in hemoglobin levels and QoL	12 weeks per patient	Effectiveness of different antianemic treatments is investigated by measuring increase of hemoglobin levels and QoL (FACT-An and FACT-GP). Baseline in hemoglobin (before treatment) is compared with hemoglobin levels after treatment. Each patient is followed for a maximum of 12 weeks to obtain data about the course of the treatment.

Countries

Germany

Outcome results